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Objective: Recent reports showed that the Endurant stent graft (Medtronic Cardiovascular, Santa Rosa, Calif) is safe and
effective for endovascular repair of abdominal aortic aneurysms (AAAs). However, due to its relatively recent intro-
duction, only short-term follow-up data are available. This study presents the 4-year results using this device.
Methods: All clinical data, including detailed anatomic information of the ﬁrst 100 consecutive patients treated with the
Endurant stent graft for an infrarenal AAA in three Dutch high-volume hospitals, were prospectively collected.
Computed tomography angiography was routinely performed before the procedure, #1 month, and at 1 year post-
endovascular aneurysm repair. Thereafter, the imaging modality during yearly follow-up was individualized (duplex
ultrasound imaging or computed tomography angiography). Patients were classiﬁed as within or outside the instructions
for use (IFU) for analysis. Study end points were primary clinical success, overall and AAA-related mortality, and sac
morphology changes and endoleak during follow-up. Estimates were obtained using Kaplan-Meier plots.
Results: The study included 100 consecutive patients (88 men) with a median age of 74 years (interquartile range [IQR],
67-79 years) and median AAA diameter of 58 mm (IQR, 55-65 mm), between December 2007 and March 2009. Twenty
patients (20%) were treated outside the IFU (18, outside proximal neck IFU, one outside iliac IFU, and one outside both
IFUs). Median follow-up was 48 months (IQR, 36-53 months), and no patients were lost. One contained rupture was
observed after 1.5 months due to graft infection. No patients had graft migration. Two type Ia endoleaks, 5 type Ib
endoleaks, and 15 type II endoleaks were found. Primary clinical success was 97%, 90%, 84% and 77% at 1, 2, 3, and
4 years, respectively. Primary clinical success was comparable for patients treated within or outside IFU (P [ .20),
although both patients outside iliac IFU needed a secondary iliac intervention. Over time, maximum aneurysm diameter
decreased $5 mm, remained stable, and increased $5 mm in 58%, 32%, and 10% of the patients, respectively. All-cause
mortality was 20% at 4 years, with a 3% AAA-related mortality.
Conclusions: The 4-year follow-up data of the Endurant stent graft for AAA treatment shows its use results in a low AAA-
related mortality with adequate prevention of rupture or aneurysm growth. Although patients with very challenging
anatomy were treated in our series, primary clinical success rates were comparable for patients treated within and outside
the IFU. However, both patients outside the iliac IFU needed a secondary iliac intervention. The knowledge of the
present results may aid in improving outcomes in the future. (J Vasc Surg 2014;59:1195-202.)Endovascular aneurysm repair (EVAR) is increasingly
seen as the primary choice of treatment for abdominal
aortic aneurysms (AAAs) for patients who are anatomically
suitable for endovascular repair.1 Since the introduction of
the latest generation of stent grafts, preliminary EVAR re-
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or tortuous, small, or calciﬁed iliac arteries showedthe Department of Vascular Surgery, University Medical Center
trecht, Utrechta; the Department of Vascular Surgery, Erasmus Medical
enter, Rotterdamb; and the Department of Vascular Surgery, St. Anto-
us Hospital, Nieuwegein.c
or conﬂict of interest: J.P.M.V. has a proctor agreement with
edtronic and is a paid consultant; H.J.M.V., F.L.M., and J.A.H. are
id consultants.
rint requests: Herman J.A. Zandvoort, MD, PhD, University Medical
enter Utrecht, Department of Vascular Surgery, Rm G.04.129, PO Box
500, 3508 GA, Utrecht, The Netherlands (e-mail: h.j.a.zandvoort@
cutrecht.nl).
editors and reviewers of this article have no relevant ﬁnancial relationships
disclose per the JVS policy that requires reviewers to decline review of any
anuscript for which they may have a conﬂict of interest.
-5214/$36.00
yright  2014 by the Society for Vascular Surgery.
://dx.doi.org/10.1016/j.jvs.2013.12.031feasibility of the procedure.2,3 The Endurant stent graft
(Medtronic Cardiovascular, Santa Rosa, Calif) received
United States Food and Drug Administration approval in
December 2010 and is widely used for EVAR.
Recent results showed that this device is safe and effec-
tive in the short term for treatment of patients with
AAAs.3-7 However, due to its relatively recent introduc-
tion, only short-term follow-up data are available. Intro-
duction in Europe, however, dates from early 2008, and
longer-term results from this geographic region are now
starting to appear. These are necessary to assess the dura-
bility of treatment with this particular stent graft. There-
fore, the purpose of this study was to analyze the 4-year
results of our ﬁrst 100 consecutive patients7 treated with
an Endurant graft for an AAA.
METHODS
Patients. This study is a follow-up study of the cohort
described by van Keulen et al7 in September 2011.
Included were the ﬁrst 100 consecutive patients who were
electively treated with the Endurant stent graft for an
infrarenal aneurysm in three high-volume, tertiary vascular
referral hospitals in The Netherlands (University Medical1195
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Rotterdam; and St. Antonius Hospital, Nieuwegein).
Follow-up. All clinical and imaging follow-up data of
these ﬁrst 100 consecutive patients were prospectively
collected in a database. Regular follow-up was performed at
1 month and 12 months after EVAR and yearly thereafter.
Computed tomography angiography (CTA) was routinely
performed #1 month after the EVAR procedure and at
1 year after EVAR. For subsequent annual follow-up visits,
the choice of the imaging modality (duplex ultrasound
[DUS] imaging or CTA) was individualized according to
local protocols.
All available CTA data sets of included patients were
transferred to a workstation (3Mensio Medical Imaging
BV, Bilthoven, The Netherlands) for analysis, with the sup-
port of a three-dimensional reconstruction with central
lumen line. Experienced physicians performed the mea-
surements, and pre-EVAR CT scans were also evaluated
for baseline aortic anatomy. The characteristics investigated
on the CTA scans were AAA diameter, existence of endo-
leaks, patency of renal arteries, diameter of the AAA neck,
and distance from the most distal renal artery to the most
proximal stent graft ring. The CTA scans were also checked
for any other EVAR-related complications.
DUS imaging was performed by experienced opera-
tors, and data on maximum aneurysm diameter, patency
of the stent graft, and patency of the native iliac/femoral
arteries, as well as any detectable endoleaks, were obtained
from the DUS report. In case of doubt or complication at
DUS imaging, an additional CT scan was performed.
All complications, secondary interventions, outpatient
department visits, readmissions, deaths, and causes of death
were documented and analyzed. Causes of death at a loca-
tion other than the initial treating hospital were investi-
gated by contacting the treating general practitioner or
responsible medical specialist.
The primary study end point was primary clinical suc-
cess, as deﬁned in the reporting standards for EVAR.8 Sec-
ondary end points were overall and AAA-related mortality,
sac morphology changes, and the occurrence of endoleak.
The morphology of the proximal aneurysm neck of the
study patients was classiﬁed as within or outside the in-
structions for use (IFU) criteria of the Endurant stent graft.
The proximal neck is considered inside IFU for the Endur-
ant stent graft if the neck diameter is 19 to 32 mm with
nonsigniﬁcant calciﬁcation and thrombus and the neck
length is $10 mm in combination with a suprarenal angu-
lation #45 and an infrarenal angulation of #60. If the
neck length is $15 mm, then a suprarenal angulation
#60 and an infrarenal angulation of #75 are accepted.
We deﬁned <50% calciﬁcation and <50% thrombus as
nonsigniﬁcant. Neck calciﬁcation and thrombus were
measured 10 mm below the most distal renal artery and
deﬁned as the percentage of the circumference calciﬁed
or covered with thrombus, respectively. Except for the
IFU of the proximal aneurysm neck, patients were also clas-
siﬁed as within or without the IFU criteria for the iliac ar-
teries. IFU criteria were an iliac diameter between 8 and25 mm and a potential distal landing zone of at least
15 mm.
Sac growth was considered if the maximum aneurysm
diameter increased by $5 mm compared with the ﬁrst
postoperative examination. Sac shrinkage was considered
if the maximum diameter was reduced by $5 mm. Deﬁni-
tions for complications and secondary interventions were
coded and described according to the reporting standards
for EVAR.8
The decision to treat an endoleak was taken according
to the most recent guidelines.9,10 This resulted in treat-
ment of all potential type I and III endoleaks. Type II
endoleaks were only treated if they were associated with
aneurysm growth. Type II endoleaks without increased
sac diameter were observed. The decision to treat limb oc-
clusion or stenosis was determined by the presence of clin-
ical symptoms.
Statistical analysis. Continuous variables are pre-
sented as median and interquartile range (IQR) for not
normally distributed variables. Differences were assessed
by nonparametric testing. Categoric variables are presented
as number and percentage. The Kaplan-Meier method was
used to assess primary clinical success and cumulative rates
of survival. The log-rank test was used to compare Kaplan-
Meier estimates between patients who were treated within
IFU and outside IFU. Signiﬁcance was assumed at P# .05.
Statistical analysis was performed with SPSS 20 software
(IBM Corp, Armonk, NY).RESULTS
Between December 2007 and March 2009, 100
consecutive elective patients (88 men) were treated with
the Endurant stent graft. The median age was 74 years
(IQR, 67-79 years). Preoperative screening for comorbid-
ities showed that most of the patients had mild to severe
systemic disease by the American Society of Anesthesiolo-
gists (ASA) Physical Status Classiﬁcation (ASA 1, 6%;
ASA 2, 45%; ASA 3, 48%; and ASA 4, 1%). The median
AAA diameter was 58 mm (IQR, 55-65 mm). All other
baseline characteristics are reported in Table I.
Of the 100 included patients with AAAs, 19 had at
least one anatomic characteristic of the proximal aneurysm
neck that was considered a violation of the IFU of the
Endurant stent graft, and one was outside the iliac IFU
as well. For an extensive description of the proximal neck
IFU violation, we refer to the previously published 1-year
results.7 In addition, one patient had an iliac anatomy
that was outside the IFU of the Endurant stent graft
because of a large iliac diameter (27 mm).
The median follow-up was 48 months (IQR, 36-
53 months; maximum, 62 months), and no patients were
lost to follow-up. Follow-up was >12 months in 88
patients, >24 months in 81 patients, >36 months in 73
patients and >48 months in 48 patients.
The median diameter of the aneurysm sac decreased
during follow-up from 58 mm (IQR, 55-65 mm) preoper-
atively to 51 mm (IQR, 42-60 mm; P < .001). In total, 22
Table II. Endoleaks during follow-up
Endoleak
Shrinkage
$5 mm, No. Stable, No.
Growth
$5 mm, No.
Type Ia . . 2
Type Ib . . 5a
Type II >30 days 4 5 6
aOne patient had both a type Ib and a type II endoleak but is shown as type
Ib endoleak because was the most likely cause of growth.
Fig 1. Kaplan-Meier survival curve shows primary clinical success
during follow-up after endovascular aneurysm repair (EVAR). SE,
Standard error.
Table I. Baseline characteristics
Parameter Median (IQR) or No.a
Maximum diameter, mm 58 (55-65)
Neck length, mm 34 (22-43)
Neck diameter, mm 27 (25-28)
Neck calciﬁcationb
<25% 83
25%-50% 13
50%-75% 4
>75% 0
Neck thrombusb
<25% 64
25%-50% 20
50%-75% 8
>75% 8
Angulation, 
Suprarenal 23 (8-38)
Infrarenal 41 (25-61)
CIA diameter,c mm
1 cm distal
Left 13 (16-20)
Right 14 (16-19)
3 cm distal
Left 14 (16-20)
Right 14 (16-19)
5 cm distal
Left 14 (16-19)
Right 14 (16-19)
EIA diameter,d mm
Left 10 (9-12)
Right 10 (9-11)
Male sex 88
Hypertension 54
Smoking 45
Diabetes 18
ASA classiﬁcation
1 6
2 45
3 48
4 1
ASA, American Society of Anesthesiologists; CIA, common iliac artery;
EIA, external iliac artery; IQR, interquartile range.
aCategoric data are presented as the number of patients positive for the
variable.
bNeck calciﬁcation and thrombus are measured 10 mm below the most
distal renal artery and deﬁned as the percentage of the circumference
calciﬁed or covered with thrombus, respectively.
cDiameters of the CIAs were measured 1, 3, and 5 cm distally of the aortic
bifurcation.
dDiameters of the EIAs were measured 1 cm distally of the iliac bifurcation.
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were detected during follow-up (Table II).
Primary clinical success. Primary clinical success
(Fig 1) was 97% at 1 year, 90% at 2 years, 84% at 3 years,
and 77% at 4 years. When patients treated outside the IFU
were compared with patients treated within the IFU
(Fig 2), no difference was observed for primary clinical
success rates (P ¼ .20). However, when only the iliac IFU
was taken into account, both patients treated outside the
iliac IFU needed an iliac reintervention. During follow-up,
secondary procedures were performed in 19 patients
(19%). In total, 27 reinterventions were performed, with
two patients requiring two reinterventions, and threepatients requiring three reinterventions (Table III).
Freedom from secondary interventions was 98%, 91%, 85%,
and 80% after 1, 2, 3, and 4 years, respectively.
Aneurysm sac growth was observed in 14 patients. A
secondary intervention was performed in 13 patients who
had aneurysm growth combined with an endoleak. Further
growth after the secondary intervention was arrested in
eight patients (62%), and shrinkage $5 mm occurred in
three patients (23%). Enlargement continued in two pa-
tients (15%). One patient, with an infected stent graft
and a type Ia endoleak requiring placement of a proximal
cuff, is discussed in detail below. Another patient under-
went embolization of a type II endoleak; however, after
the embolization, the aneurysm diameter of this patient
increased 5 mm in 18 months. Because no new endoleak
was visible and there was an adequate proximal and distal
sealing, this patient was kept under strict surveillance.
The patient without a detectable endoleak and growth
was also kept under strict surveillance.
Proximal cuff placement was performed in three pa-
tients (all treated within the proximal neck IFU) after
38 days, 13 months, and 41 months. Initial proximal
neck diameters were 21 mm, 32 mm, and 29 mm and
Fig 2. Kaplan-Meier survival curves show primary clinical success
in patients treated inside and outside instructions for use (IFU)
criteria during follow-up after endovascular aneurysm repair
(EVAR). SE, Standard error.
Table III. Secondary procedures performed during
follow-up
Type of procedure
Procedures,
No.
Time during
FU, months
Proximal cuff placement 3 1, 13, 41
Limb extension 8
Type Ib endoleak 6 21, 28, 33, 40, 54, 57
Short sealing 2 15, 52
Embolization for type II
endoleak
6 17, 18, 25, 26, 36, 38
Conversion for infected
stent graft
1 21
Treatment for iliac limb
occlusion
6
Embolectomy 2 1 day post-op, 12
Thrombolysis 4 19, 22, 37, 52
Other procedures 3
Balloon-expandable stent
for continuing type Ia
endoleak
1 29
Repeat ballooning stent
for continuing type Ia
endoleak
1 32
Graft limb stenting with a new
graft limb because of <50%
symptomatic stenosis
1 27
FU, Follow-up.
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enlargement after EVAR occurred in all three patients
(30 mm, 13 mm, and 10 mm). The patient with 30-mm
growth had a large type Ia endoleak combined with a con-
tained AAA rupture. Owing to stent graft infection, the
aneurysm had grown with complete disappearance of theinfrarenal aneurysm neck. The patient also received intrave-
nous antibiotics, but this could not prevent death from
sepsis, 65 days after the initial EVAR. The patient with a
13-mm growth had progressive dilatation of the proximal
neck resulting in insufﬁcient seal length, although no
type Ia endoleak was found.
A limb extension procedure was performed in seven pa-
tients and was successful in all cases. Five patients (5%)
were treated for a type Ib endoleak and two patients
(2%) for short distal sealing. Two patients were outside
the iliac IFU because the iliac diameter exceeded the rec-
ommended 25 mm. Four patients with a type Ib endoleak
also had continuing dilatation of the iliac arteries during
follow-up, indicating progression of the aneurysmatic dis-
ease. Data on sealing lengths and initial iliac diameters
for all these patients are reported in Table IV.
Furthermore, a stent graft limb occlusion occurred in
four patients (4%) during follow-up at 1 day, and at 12,
37, and 52 months after the initial EVAR. Three of these
patients were successfully treated endovascularly, whereas
in the remaining patient, endovascular therapy failed.
One patient (with an occlusion after 12 months) developed
two reocclusions, 7 and 10 months after the ﬁrst embolec-
tomy. All four patients were treated within IFU for the
Endurant stent graft.
Mortality and aneurysm-related death. Nineteen pa-
tients (19%) died during follow-up. Causes of death were
aneurysm-related in 3, malignancy in 3, sepsis in 3 (1 from
respiratory, 1 gastrointestinal, and 1 unknown focus),
cardiac disease in 2, gastrointestinal bleeding in 1, preop-
eratively existent renal insufﬁciency in 1, and unknown
in 6.
The three aneurysm-related deaths occurred within the
ﬁrst year of follow-up. For an extensive description of the
AAA-related deaths, we refer to the previously published
1-year results.7 Overall patient survival rates (Fig 3) were
88% at 1 year, 84% at 2 years, 82% at 3 years, and 80% at
4 years. Mortality rates did not differ between patients
who required a secondary intervention and patients
without a secondary intervention, with survival rates after
4 years of 86% and 79%, respectively (P ¼ .59). Further-
more, survival rates for patients treated within IFU were
comparable to survival rates for those treated outside
IFU (81% and 79% at 4 years, respectively; P ¼ .94).
Aneurysm sac behavior and endoleak. The median
diameter of the aneurysm sac decreased from 58 mm
(IQR, 55-65 mm) preoperatively to 51 mm (IQR, 42-
60 mm; P < .001) during follow-up. Fourteen patients
(14%) had at any moment during follow-up growth
$5 mm. Six of these patients (43%) had a type II endoleak
and one patient had a type Ib and type II endoleak. A type
Ia endoleak was detected in two patients, and four patients
had a type Ib endoleak (Table II). One patient had no
detectable endoleak on CTA.
On the last available imaging follow-up, maximum
aneurysm diameter decreased $5 mm since the initial
EVAR in 58% of the patients and remained stable in
32%, whereas 10% of the patients had growth $5 mm.
JOURNAL OF VASCULAR SURGERY
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The 1-year follow-up results of this study population
were published in 2011 when the ﬁrst 100 consecutive pa-
tients of three Dutch high-volume hospitals had their
1-year follow-up visit.7 In the current report, we analyzed
the follow-up results of these patients after a median
follow-up of 48 months.
Primary clinical success was 97% at 1 year, 90% at
2 years, 84% at 3 years, and 77% at 4 years. At a median
follow-up of 48 months, maximum aneurysm diameter
decreased $5 mm since the initial EVAR in 58% of the
patients and remained stable in 32%, while 10% of the
patients had growth $5 mm.
It is important to mention that this study also includes
patients with a challenging anatomy for endovascular repair
of an infrarenal AAA. The Endurant stent graft is the stent
graft of primary choice in the cooperating centers because
it also offers the possibility of treating patients with a chal-
lenging proximal neck due to more angulation or a larger
diameter. As we showed in our previous study,7 up to 48%
of the patients would be outside the IFU, depending on
which of the commercially available stent grafts at that
time would have been implanted: 48% outside the IFU for
the Zenith stent graft (Cook Medical, Bloomington, Ind),
40% outside the IFU for the Excluder stent graft (W. L.
Gore and Associates, Flagstaff, Ariz), and 27% outside the
IFU for the Talent stent graft (Medtronic Cardiovascular).
Even with the generally more liberal IFU of the Endur-
ant stent graft, 20% of patients were outside the recom-
mendation for this device. All patients whose deaths were
aneurysm-related were treated within IFU, and primary
clinical success was comparable for patients treated within
or outside IFU, although both patients treated outside
the iliac IFU needed an iliac reintervention. We did not
statically compare iliac IFU with iliac non-IFU patients
due to sample size.
Considering the possible increase in complication rates
resulting from the challenging anatomy presented in this
cohort, this study revealed low AAA-related mortality.
All-cause mortality was 20% after 4 years, with only a 3%
AAA-related mortality at 1 and 4 years, all cases being peri-
operative deaths or resulting from infection. The all-cause
mortality rate, despite being comparable or lower than
more historical series,11,12 can still be considered signiﬁ-
cant. This is possibly explained by the age and comorbid-
ities of this population, reﬂected in the ASA classiﬁcation
(48% of the patients were ASA 3). Moreover, most patient
deaths occurred during the ﬁrst year of follow-up (all-cause
mortality was 12% after 1 year), and no aneurysm-related
deaths occurred thereafter. In the patients who died of un-
known causes, aneurysm-related death was unlikely because
no patients demonstrated AAA enlargement at their latest
follow-up assessment, and only one patient had a demon-
strable complication (a type II endoleak without sac
enlargement) on the last imaging surveillance examination.
Globally, a signiﬁcant reduction in median AAA aneu-
rysm diameter was observed over time, from 58 mm to51 mm (P < .001). The diameter remained stable in
one-third of patients, and nearly 60% had shrinkage
>5 mm, suggesting successful aneurysm exclusion in a
high percentage of patients. The rates of sac shrinkage in
this cohort appear comparable to previously reported rates
of other stent grafts of 60.9% after 3 years, 62.2% after
5 years, and 63% after 5 years.13-15
In 19 patients, one or multiple secondary procedures
were performed. Placement of an iliac extension for treat-
ment of a type Ib endoleak or short distal sealing was the
most common secondary procedure (n ¼ 8) in seven
patients.
Primary clinical success after 4 years was 77%. This rate
is comparable to series with the Talent stent graft, Endur-
ant’s predecessor.14,16-18 Because no other 4-year results of
the Endurant are available, we could not compare our re-
sults with other studies. On one hand, device-speciﬁc
studies of other currently commercially available stent
grafts are scarce but show comparable primary clinical suc-
cess rate after 3 years.19,20 On the other hand, Pratesi
et al21 and Baptiste et al22 reported a freedom of reinter-
vention rate of 94.6% and 92% after 3 years. However,
only approximately one-third of patients were available
for analysis at this point.
Secondary interventions were generally successful,
particularly the interventions for endoleaks combined
with growth of the aneurysm. In 85% of the cases, the
aneurysm growth was stopped or even shrinkage was
shown. This underlines the importance of an adequate
follow-up so that problems can be detected and treated.
A stent graft limb occlusion occurred in four patients
(4%). This occlusion rate of 4% is comparable with other
studies with this particular stent graft3,4,23 but is still sub-
stantial and seems higher compared with other simulta-
neously available grafts.20-22 However, comparing the
results is difﬁcult because of the heterogeneity in patient
population and follow-up duration.
We recently speciﬁcally looked into the occlusions and
suggest that the occlusion rate may be reduced by a more
liberal intraoperative and early postoperative (re)interven-
tion strategy.23 The inclusion of patients with unfavorable
anatomy and obstructive disease may probably also
contribute to an increased chance of endograft occlusion,
even if they are considered within IFU.23
Although most stent graft occlusions have been sug-
gested to occur due to technical errors,23 a review of the
ﬁrst postoperative CTA scans could not identify any
anatomic or technical reasons that could have led to the
occlusion of a limb during follow-up in one patient. How-
ever, a possible explanation for the occlusion was found in
the remaining three patients. One occlusion had probably
an anatomic reason. This patient had a very small external
iliac diameter (7 mm) in relation to the common iliac diam-
eter (21 mm) that potentially limited the ﬂow considerably.
The occlusion in one patient, with ventricular tachycardia,
was likely caused by the low ﬂow state. One other patient
with a limb occlusion presented with several other
Table IV. Patients with distal extensiona
Patient Indication
Initial iliac diameter
R/L, mm
Diameter iliac limb
R/L, mm
Potential ﬁxation
zone pre-op
R/L, mm
1 Type Ib endoleak; progressive disease iliac artery 19/18 20/20 $15/$15
2 Type Ib endoleak; progressive disease iliac artery 21/26 24/28 $15/10
3b Type Ib endoleak left; type Ib endoleak right;
progressive disease iliac artery
21/18 24/20 $15/$15
4 Type Ib endoleak 11/14 13/16 $15/$15
5 Type Ib endoleak; progressive disease iliac artery;
retraction of stent graft
27/23 28/28 10/$15
6 Short iliac seal 20/16 24/20 $15/$15
7 Short iliac seal 18/18 20/20 $15/$15
IFU, Instructions for use; L, left; N/A, not available; R, right.
aThe postoperative sealing length was measured on the ﬁrst postoperative computed tomography angiography (CTA; #30 days). The sealing length before
secondary intervention represents the sealing length on the last CTA before the iliac extension, and the sealing length after secondary intervention represents
the sealing length on the ﬁrst CTA after the placement of the iliac extension.
bThe left limb was extended 40 months after endovascular aneurysm repair (EVAR) and the right limb after 57 months.
cOnly a duplex ultrasound (DUS) assessment was performed after the secondary intervention.
Fig 3. Kaplan-Meier survival curve shows overall survival after
endovascular aneurysm repair (EVAR). SE, Standard error.
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dual antiplatelet therapy, which suggests an unrecognized
coagulation disorder.
The number of distal extensions required after implan-
tation was relatively high in this study population and
contributed to a large proportiondeight of 27 (30%)dof
the secondary interventions. Five patients underwent a sec-
ondary intervention for a type Ib endoleak and also two for
short distal sealing of the graft. The maximum iliac diam-
eter exceeded the recommended 25 mm of the IFU in
two patients. In ﬁve of seven patients (71%), the postoper-
ative iliac sealing zone ($15 mm sealing) was too short,
probably due to the attempt to use as few endovascular
components as possible. The distal sealing zone shortenedduring follow-up, causing in ﬁve patients a type Ib endo-
leak. This was accompanied in four of these ﬁve patients
by a dilatation of their iliac arteries. Disease progression
could possibly have led to further dilatation so that the seal-
ing waned and an endoleak could develop. Another oppor-
tunity is that a too liberal interpretation of the IFU for the
iliac landing zone or suboptimal placement of the distal
graft extensions in the iliac artery resulted in shortening
of the distal sealing zone. The patient with no sealing in
the right limb at the ﬁrst postoperative CTA 1 month after
EVAR could be considered as technical failure, and this was
probably caused by misinterpretation of the ﬂuoroscopy
images during the initial EVAR procedure.
On the basis of our experience with loss of distal seal
during follow-up, we enhanced the focus on distal ﬁxation
and sealing and now try to achieve a distal landing zone of
at least 30 mm.
Although all data were prospectively collected in a
multicenter cohort, one of the limitations of this study is
the relatively small number of patients. In addition, this
study describes the ﬁrst experience with the Endurant stent
graft in all three participating hospitals. We expect that re-
sults may further improve as experience with this stent graft
increases. An example is our extra attention regarding the
length of the distal landing zone.
Another limitation is the individualized choice of imag-
ing modality according to local protocols in the different
hospitals. Especially for follow-up visits after several years
without any imaging complication, DUS was often used.
Although this avoids radiation exposure to patients,
DUS is less sensitive than CTA for the detection of
endoleaks.21,24
CONCLUSIONS
This study reveals the 4-year follow up data of the
Endurant stent graft for AAA treatment. This stent graft
has a more liberal IFU than most other contemporary de-
vices; however, its use results in a low AAA-related
Within
iliac IFU
Sealing length post-op
R/L iliac, mm
Aneurysm growth
at the second intervention
Sealing length before
second intervention
R/L iliac, mm
Side distal
extension
Sealing length after
second intervention
R/L iliac, mm
Yes 39/12 Growth 10/0 L 12/30
No 0/3 Growth 0/0 Both 24/10
Yes 30/28 Growth 15/0 0/38 L R 16/43 N/Ac
Yes 16/22 Growth 13/0 Both 34/76
No 13/25 Growth 0/0 Both 44/58
Yes 26/3 Growth 25/0 L 20/23
Yes 17/14 Shrinkage 13/2 L N/Ac
Table IV. Continued.
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rysm growth. Although patients with a challenging prox-
imal neck anatomy were treated in our series, secondary
intervention rates were comparable for patients treated
within and outside the IFU for the proximal neck. Howev-
er, the number of distal extensions required after implanta-
tion was relatively high in this study population and
probably caused by a too liberal interpretation of the IFU
for the iliac landing zone or suboptimal placement of the
distal graft extensions in the iliac artery. The knowledge
of the present results may aid in improving outcomes in
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